Curative Loco-regional Therapies for Early Hepatocellular Carcinoma: Is Combination Effective?

Sae Hwan Lee

doi:10.4166/kjg.2019.73.3.121

Journal List > Korean J Gastroenterol > v.73(3) > 1119373

Go to TopGo to Top Go to BottomGo to Bottom

See the article "".

TOOLS

Lee: Curative Loco-regional Therapies for Early Hepatocellular Carcinoma: Is Combination Effective?

Editorial

The Korean Journal of Gastroenterology 2019; 73(3): 121-123.

Published online: 27 March 2019

DOI: https://doi.org/10.4166/kjg.2019.73.3.121

Curative Loco-regional Therapies for Early Hepatocellular Carcinoma: Is Combination Effective?

Sae Hwan Lee

Division of Gastroenterology, Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, Korea.

Correspondence to: Sae Hwan Lee, Division of Gastroenterology, Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, 31 Suncheonhyang 6-gil, Dongnam-gu, Cheonan 31151, Korea. Tel: +82-41-570-3692, Fax: +82-41-574-5762, stevesh@sch.ac.kr

Korean Society of Gastroenterology

(open-access):

This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Article: Efficacy and Safety of Combined Radiofrequency Ablation with Transarterial Chemoembolization in Patients with Barcelona Clinic Liver Cancer Stage A Hepatocellular Carcinoma Ineligible for Curative Treatment ([Related article:] Korean J Gastroenterol 2019;73:167-176 )

Notes

^{Financial support} None.

^{Conflict of interest} None.

References

1. Li L, Zhao W, Wang M, et al. Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis. BMC Gastroenterol. 2018; 18:138.

2. Galle PR, Forner A, Llovet JM, et al. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018; 69:182–236.

3. Shiina S, Tateishi R, Arano T, et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol. 2012; 107:569–577. quiz 578.

4. Liu Z, Gao F, Yang G, et al. Combination of radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: an up-to-date meta-analysis. Tumour Biol. 2014; 35:7407–7413.

5. Wang X, Hu Y, Ren M, Lu X, Lu G, He S. Efficacy and safety of radiofrequency ablation combined with transcatheter arterial chemoembolization for hepatocellular carcinomas compared with radiofrequency ablation alone: a time-to-event meta-analysis. Korean J Radiol. 2016; 17:93–102.

6. Choe WH, Kim YJ, Park HS, Park SW, Kim JH, Kwon SY. Short-term interval combined chemoembolization and radiofrequency ablation for hepatocellular carcinoma. World J Gastroenterol. 2014; 20:12588–12594.

7. Wang WD, Zhang LH, Ni JY, et al. Radiofrequency ablation combined with transcatheter arterial chemoembolization therapy versus surgical resection for hepatocellular carcinoma within the Milan criteria: a meta-analysis. Korean J Radiol. 2018; 19:613–622.

8. Kim AR, Park E, Kwon SY, et al. Efficacy and safety of combined radiofrequency ablation with transarterial chemoembolization in patients with BCLC stage A hepatocellular carcinoma ineligible for curative treatment. Korean J Gastroenterol. 2019; 73:167–176.

9. Chen R, Geschwind JF, Wang Z, Tacher V, Lin M. Quantitative assessment of lipiodol deposition after chemoembolization: comparison between cone-beam CT and multidetector CT. J Vasc Interv Radiol. 2013; 24:1837–1844.

10. Ishikawa T, Abe S, Hoshii A, et al. Cone-beam computed tomography correlates with conventional helical computed tomography in evaluation of lipiodol accumulation in HCC after chemoembolization. PLoS One. 2016; 11:e0145546.

11. Jun BG, Kim SG, Kim YD, et al. Combined therapy of transarterial chemoembolization and stereotactic body radiation therapy versus transarterial chemoembolization for ≤5cm hepatocellular carcinoma: propensity score matching analysis. PLoS One. 2018; 13:e0206381.

12. Paik EK, Kim MS, Jang WI, et al. Benefits of stereotactic ablative radiotherapy combined with incomplete transcatheter arterial chemoembolization in hepatocellular carcinoma. Radiat Oncol. 2016; 11:22.

13. Kudo M, Izumi N, Kokudo N, et al. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice guidelines proposed by the Japan society of hepatology (JSH) 2010 updated version. Dig Dis. 2011; 29:339–364.

TOOLS

ORCID iDs: Sae Hwan Lee
https://orcid.org/0000-0001-8320-5914
Similar articles